secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOVIE INC. (BIVI)
CIK:        0001580149
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001520138-24-000105
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025
--------------------------------------------------------------------------------

- Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.
- Phase 2b monotherapy trial of NE3107 in Parkinson's planned for late summer 2024; 100–150 patients.
- Phase 3 Alzheimer's trial postponed to early 2025 to use once-daily NE3107 formulation.
- BIV201 Phase 3 in ascites delayed pending partnership; FDA guidance received.
- Previous NE3107 data showed 68% slowing on CDR-SB in AD and improved non-motor symptoms in PD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580149/000152013824000105/0001520138-24-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580149/000152013824000105/bivi-20240311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001520138-24-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer